<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE trials [
<!ELEMENT trials (trial+)>

<!ELEMENT trial (main,contacts,countries,criteria,health_condition_code,health_condition_keyword,intervention_code,
          intervention_keyword,primary_outcome,secondary_outcome,secondary_sponsor,secondary_ids,source_support,ethics_reviews)>

<!ELEMENT main (trial_id,utrn?,reg_name,date_registration,primary_sponsor,public_title,acronym?,scientific_title,scientific_acronym?,
          date_enrolment,type_enrolment,target_size,recruitment_status,url?,study_type,study_design,phase,hc_freetext?,i_freetext?,results_actual_enrolment,results_date_completed,results_url_link,results_summary,           results_date_posted,results_date_first_publication,results_baseline_char,results_participant_flow,results_adverse_events,results_outcome_measures,results_url_protocol,results_IPD_plan, results_IPD_description)>
<!ELEMENT trial_id (#PCDATA)>
<!ELEMENT utrn (#PCDATA)>
<!ELEMENT reg_name (#PCDATA)>
<!ELEMENT date_registration (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT primary_sponsor (#PCDATA)>
<!ELEMENT public_title (#PCDATA)>
<!ELEMENT acronym (#PCDATA)>
<!ELEMENT scientific_title (#PCDATA)>
<!ELEMENT scientific_acronym (#PCDATA)>
<!ELEMENT date_enrolment (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT type_enrolment (#PCDATA)>
<!ELEMENT target_size (#PCDATA)>
<!ELEMENT recruitment_status (#PCDATA)><!-- Pending,Recruiting,Suspended,Complete,Other -->
<!ELEMENT url (#PCDATA)>
<!ELEMENT study_type (#PCDATA)><!-- interventional,observational -->
<!ELEMENT study_design (#PCDATA)>
<!ELEMENT phase (#PCDATA)>
<!ELEMENT hc_freetext (#PCDATA)>
<!ELEMENT i_freetext (#PCDATA)>
<!ELEMENT results_actual_enrolment (#PCDATA)>
<!ELEMENT results_date_completed (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_url_link (#PCDATA)>
<!ELEMENT results_summary (#PCDATA)>
<!ELEMENT results_date_posted (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_date_first_publication (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_baseline_char (#PCDATA)>
<!ELEMENT results_participant_flow (#PCDATA)>
<!ELEMENT results_adverse_events (#PCDATA)>
<!ELEMENT results_outcome_measures (#PCDATA)>
<!ELEMENT results_url_protocol (#PCDATA)>
<!ELEMENT results_IPD_plan (#PCDATA)>
<!ELEMENT results_IPD_description (#PCDATA)>


<!ELEMENT contacts (contact+)>
<!ELEMENT contact (type,firstname,middlename,lastname,address,city,country1,zip,telephone,email,affiliation)>
<!ELEMENT type (#PCDATA)><!-- Public,Scientific -->
<!ELEMENT firstname (#PCDATA)>
<!ELEMENT middlename (#PCDATA)>
<!ELEMENT lastname (#PCDATA)>
<!ELEMENT address (#PCDATA)>
<!ELEMENT city (#PCDATA)>
<!ELEMENT country1 (#PCDATA)>
<!ELEMENT zip (#PCDATA)>
<!ELEMENT telephone (#PCDATA)>
<!ELEMENT email (#PCDATA)>
<!ELEMENT affiliation (#PCDATA)>

<!ELEMENT countries (country2+)>
<!ELEMENT country2 (#PCDATA)>

<!ELEMENT criteria (inclusion_criteria,agemin,agemax,gender,exclusion_criteria)>
<!ELEMENT inclusion_criteria (#PCDATA)>
<!ELEMENT agemin (#PCDATA)>
<!ELEMENT agemax (#PCDATA)>
<!ELEMENT gender (#PCDATA)>
<!ELEMENT exclusion_criteria (#PCDATA)>

<!ELEMENT health_condition_code (hc_code+)>
<!ELEMENT hc_code (#PCDATA)>

<!ELEMENT health_condition_keyword (hc_keyword+)>
<!ELEMENT hc_keyword (#PCDATA)>

<!ELEMENT intervention_code (i_code+)>
<!ELEMENT i_code (#PCDATA)>

<!ELEMENT intervention_keyword (i_keyword+)>
<!ELEMENT i_keyword (#PCDATA)>

<!ELEMENT primary_outcome (prim_outcome+)>
<!ELEMENT prim_outcome (#PCDATA)>

<!ELEMENT secondary_outcome (sec_outcome+)>
<!ELEMENT sec_outcome (#PCDATA)>

<!ELEMENT secondary_sponsor (sponsor_name+)>
<!ELEMENT sponsor_name (#PCDATA)>

<!ELEMENT secondary_ids (secondary_id+)>
<!ELEMENT secondary_id (sec_id,issuing_authority)>
<!ELEMENT sec_id (#PCDATA)>
<!ELEMENT issuing_authority (#PCDATA)>

<!ELEMENT source_support (source_name+)>
<!ELEMENT source_name (#PCDATA)>

<!ELEMENT ethics_reviews (ethics_review+)>
<!ELEMENT ethics_review (status,approval_date,contact_name,contact_address,contact_phone,contact_email)>
<!ELEMENT status (#PCDATA)><!-- Not approved,Approved,NA -->
<!ELEMENT approval_date (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT contact_name (#PCDATA)>
<!ELEMENT contact_address (#PCDATA)>
<!ELEMENT contact_phone (#PCDATA)>
<!ELEMENT contact_email (#PCDATA)>
]>
<trials>
  <trial>
    <main>
      <trial_id>IRCT20230312057698N1</trial_id>
      <utrn></utrn>
      <reg_name>IRCT</reg_name>
      <date_registration>2023-03-29</date_registration>
      <primary_sponsor>Babol University of Medical Sciences</primary_sponsor>
      <public_title>Investigating the effect of Oropharyngeal colostrum in the prevention of  late-onset sepsis in preterm infants admitted to neonatal intensive care unit by extraoral massage method</public_title>
      <acronym>OPT,OAC,C-OIT</acronym>
      <scientific_title>Investigating the effect of Oropharyngeal colostrum in the prevention of  late-onset sepsis in preterm infants admitted to neonatal intensive care unit by extraoral massage method</scientific_title>
      <scientific_acronym></scientific_acronym>
      <date_enrolment>2023-04-09</date_enrolment>
      <type_enrolment>anticipated</type_enrolment>
      <target_size>70</target_size>
      <recruitment_status>Complete</recruitment_status>
      <url>https://irct.ir/trial/69281</url>
      <study_type>interventional</study_type>
      <study_design>Randomization: Randomized, Blinding: Double blinded, Placebo: Not used, Assignment: Parallel, Purpose: Prevention, Randomization description: In this study, a parallel randomized controlled trial (parallel randomized controlled trial) considering that not all babies are included in the study at the same time and researchers cannot predict in advance which group each baby who is included in the study will belong to, for allocation Block randomization will be used to assign each baby to one of the two groups. In order to hide the random allocation, the codes created by the software will be placed in opaque envelopes so that it is not clear which group the next person will be assigned to. In order to hide the random allocation, the codes created by the software will be placed in opaque envelopes so that it is not clear which group the next person will be assigned to. In this study, the participating infants will be assigned to one of two control and intervention groups according to the random block division protocol (produced by Random Allocation Software) with a ratio of 1:1 and in blocks of 6, so that the researcher It cannot predict which intervention group the next person is placed in. The codes will be placed in the opaque envelopes, and with the entry of each new person, the envelope will be opened and the person's belonging to the relevant group will be determined, Blinding description: Regarding the blinding method, this design is double-blind. In this study, the researcher and the nurses of the executive team are informed about the goals of the project and the groups, but the baby's parents, the evaluator (neonatal doctor) and the analyst (the person who performs the statistical analysis) are not aware of the groups.</study_design>
      <phase>N/A</phase>
      <hc_freetext>late-onset sepsis.</hc_freetext>
      <i_freetext>Intervention 1: Intervention group: In the intervention group, 0.4 ml (4 units) of mother's colostrum was drawn into a 1 ml syringe (insulin syringe) and 0.2 ml (2 units) on each side of the mouth on the gum surface (buccal cavities). ), cheek, palate, and tongue surface every 3 hours for 7 days, and each cheek is massaged from the outside of the mouth for at least 10 seconds using the index finger. Intervention 2: Control group: In the control group, routine oral care of the neonatal intensive care unit will be performed. In this group, mother's colostrum in the amount of 0.2 ml of colostrum is poured into the baby's mouth as a mouthwash every 3 hours for 7 days and cleaned with a swab.</i_freetext>
      <results_actual_enrolment></results_actual_enrolment>
      <results_date_completed></results_date_completed>
      <results_url_link></results_url_link>
      <results_summary></results_summary>
      <results_date_posted></results_date_posted>
      <results_date_first_publication></results_date_first_publication>
      <results_baseline_char></results_baseline_char>
      <results_participant_flow></results_participant_flow>
      <results_adverse_events></results_adverse_events>
      <results_outcome_measures></results_outcome_measures>
      <results_url_protocol></results_url_protocol>
      <results_IPD_plan>Undecided - It is not yet known if there will be a plan to make this available</results_IPD_plan>
      <results_IPD_description>Justification or reason for indecision in sharing IPD is There is no further information.</results_IPD_description>
    </main>
    <contacts>
      <contact>
        <type>public</type>
        <firstname>Neda behroj</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Mazandaran, Babol, Ganj Afrooz Road, Babol University of Medical Sciences - Faculty of Nursing and Midwifery - Department of Nursing</address>
        <city>Babol</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>4841849533</zip>
        <telephone>+98 11 3474 1827</telephone>
        <email>nedabehroj63@gmail.com</email>
        <affiliation>Babol University of Medical Sciences</affiliation>
      </contact>
      <contact>
        <type>scientific</type>
        <firstname>Parvin Aziznejad Roshan</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Mazandaran-Babol - Ganj Afroz Road - Babol University of Medical Sciences - Faculty of Nursing and Midwifery - Department of Nursing</address>
        <city>Babol</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>۴۷۱۷۶-۴۷۷۴۵</zip>
        <telephone>+98 11 3219 0181</telephone>
        <email>aziznejadroshan@yahoo.com</email>
        <affiliation>Babol University of Medical Sciences</affiliation>
      </contact>
    </contacts>
    <countries>
      <country2>Iran (Islamic Republic of)</country2>
    </countries>
    <criteria>
      <inclusion_criteria>Premature infants with a gestational age between 28 and 32
Premature infants without congenital abnormalities (digestive disorders) or genetic syndromes
Premature infants without mechanical ventilation
infant being NPO
Not having early sepsis or not having early sepsis risk factors
The mother's absence of active viral infections during pregnancy and childbirth</inclusion_criteria>
      <agemin>1 day</agemin>
      <agemax>2 days</agemax>
      <gender>Both</gender>
      <exclusion_criteria>The infant's condition is not stable during the intervention more than twice (loss of saturation, bradycardia,...)
Parents withdraw from continuing the research project or infants die before 7 days
infants need urgent surgery</exclusion_criteria>
    </criteria>
    <health_condition_code>
      <hc_code>P36</hc_code>
    </health_condition_code>
    <health_condition_keyword>
      <hc_keyword>Bacterial sepsis of newborn</hc_keyword>
    </health_condition_keyword>
    <intervention_code>
      <i_code>Prevention</i_code>
      <i_code>Prevention</i_code>
    </intervention_code>
    <intervention_keyword>
      <i_keyword>Intervention group: In the intervention group, 0.4 ml (4 units) of mother's colostrum was drawn into a 1 ml syringe (insulin syringe) and 0.2 ml (2 units) on each side of the mouth on the gum surface (buccal cavities). ), cheek, palate, and tongue surface every 3 hours for 7 days, and each cheek is massaged from the outside of the mouth for at least 10 seconds using the index finger.</i_keyword>
      <i_keyword>Control group: In the control group, routine oral care of the neonatal intensive care unit will be performed. In this group, mother's colostrum in the amount of 0.2 ml of colostrum is poured into the baby's mouth as a mouthwash every 3 hours for 7 days and cleaned with a swab.</i_keyword>
    </intervention_keyword>
    <primary_outcome>
      <prim_outcome>Late-onset sepsis. Timepoint: 72 hours after birth. Method of measurement: In order to distinguish clinical sepsis from other differential diagnoses in the intensive care unit of newborns, two factors CRP (C-reactive protein) and PCT (procalcitonin) are checked for suspected babies.Clinical sepsis by examining 6 criteria that include general appearance symptoms (temperature instability, paleness, skin reticulation or motilization, jaundice, bruising, petechiae) and nervous system symptoms (lethargy or irritability, hypertonia or hypotonia, loud crying) loud, trembling, restlessness) and symptoms of the cardiovascular system (tachycardia or bradycardia, hypotension, cyanosis) and symptoms of the respiratory system (apnea or tachypnea, decrease in blood oxygen saturation, hearing the sound of a baby moaning or grunting, drawn in chest muscles or retraction) and digestive system symptoms (abdominal distention, vomiting, food intolerance, diarrhea) and urinary reproductive system symptoms (decrease in urinary output or oliguria)] are determined.</prim_outcome>
    </primary_outcome>
    <secondary_outcome>
      <sec_outcome></sec_outcome>
    </secondary_outcome>
    <secondary_sponsor>
      <sponsor_name></sponsor_name>
    </secondary_sponsor>
    <secondary_ids>
      <secondary_id>
        <sec_id></sec_id>
        <issuing_authority></issuing_authority>
      </secondary_id>
    </secondary_ids>
    <source_support>
      <source_name>Babol University of Medical Sciences</source_name>
    </source_support>
    <ethics_reviews>
      <ethics_review>
        <status>Approved</status>
        <approval_date>2023-03-11</approval_date>
        <contact_name>Ethics Committee of Babol University of Medical Sciences</contact_name>
        <contact_address>Mazandaran, Babol, Ganj Afrooz Road, Babol University of Medical Sciences - Faculty of Nursing and Midwifery - Department of Nursing Babol Mazandaran Iran (Islamic Republic of)</contact_address>
        <contact_phone></contact_phone>
        <contact_email></contact_email>
      </ethics_review>
    </ethics_reviews>
  </trial>
</trials>
